Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
S. Korea not to attend Sado mine memorial: foreign ministry
[THE INVESTOR] Archigen Biotech, a 50:50 joint venture between Samsung BioLogics and Astrazeneca UK established in 2014, has recently resumed its stalled biosimilar development project.
According to industry sources on Aug. 2, the company has applied for US Food and Drug Administration’s approval to initiate phase 1 of clinical trials for SAIT101 in June.
According to industry sources on Aug. 2, the company has applied for US Food and Drug Administration’s approval to initiate phase 1 of clinical trials for SAIT101 in June.
SAIT101 is a biosimilar version of rituximab, more commonly known as Roche’s Rituxan, used to treat non-Hodgkin’s lymphoma and autoimmune diseases. Also known as MabThera in South Korea and Europe, it is among the top five biological drugs sold worldwide, reaching US$7.3 billion in annual sales last year. Rituxan’s patent in US expires in 2018.
“Samsung’s bio businesses have two axis, CMO under BioLogics and biosimilar development under Bioepis, but with this it is strengthening the development sector,” an industry source said adding that “it can be understood as a step to expanding itself in the bio industry.”
By Hwang You-mee (glamazon@heraldcorp.com)
